ATE437855T1 - (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit - Google Patents
(4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheitInfo
- Publication number
- ATE437855T1 ATE437855T1 AT05740478T AT05740478T ATE437855T1 AT E437855 T1 ATE437855 T1 AT E437855T1 AT 05740478 T AT05740478 T AT 05740478T AT 05740478 T AT05740478 T AT 05740478T AT E437855 T1 ATE437855 T1 AT E437855T1
- Authority
- AT
- Austria
- Prior art keywords
- indol
- tetrahydro
- alzheimer
- disease
- treatment
- Prior art date
Links
- -1 (4,5,6,7-TETRAHYDRO-1H-INDOL-7-YL)ACETIC ACID DERIVATIVES Chemical class 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0410238.0A GB0410238D0 (en) | 2004-05-07 | 2004-05-07 | Therapeutic agents |
| PCT/GB2005/001756 WO2005108362A1 (en) | 2004-05-07 | 2005-05-06 | (4, 5, 6, 7-tetrahydro-1-h-indol-7-yl) acetic acid derivatives for treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437855T1 true ATE437855T1 (de) | 2009-08-15 |
Family
ID=32482866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05740478T ATE437855T1 (de) | 2004-05-07 | 2005-05-06 | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7728022B2 (de) |
| EP (1) | EP1748982B1 (de) |
| JP (1) | JP2007536360A (de) |
| CN (1) | CN1950337A (de) |
| AT (1) | ATE437855T1 (de) |
| AU (1) | AU2005240830B2 (de) |
| CA (1) | CA2565214A1 (de) |
| DE (1) | DE602005015697D1 (de) |
| GB (1) | GB0410238D0 (de) |
| WO (1) | WO2005108362A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0522908D0 (en) * | 2005-11-10 | 2005-12-21 | Merck Sharp & Dohme | Therapeutic agents |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2008113835A1 (en) * | 2007-03-21 | 2008-09-25 | Novartis Ag | Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one |
| WO2009086277A1 (en) | 2007-12-20 | 2009-07-09 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| WO2010071741A1 (en) | 2008-12-16 | 2010-06-24 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
| WO2015109109A1 (en) | 2014-01-15 | 2015-07-23 | Forum Pharmaceuticals Inc. | Fused morpholinopyrimidines and methods of use thereof |
| JP2018505176A (ja) | 2015-01-29 | 2018-02-22 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | スピロフラノン化合物、それらの誘導体、及びそれらを調製する方法 |
| US9802927B2 (en) | 2015-06-10 | 2017-10-31 | Denali Therapeutics, Inc. | Oxadiazine compounds and methods of use thereof |
| CN109970681A (zh) * | 2019-04-19 | 2019-07-05 | 安徽海康药业有限责任公司 | 一种瑞格列奈的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5118427B2 (de) | 1972-11-01 | 1976-06-09 | ||
| JP2001522884A (ja) * | 1997-11-14 | 2001-11-20 | イーライ・リリー・アンド・カンパニー | アルツハイマー病の処置方法 |
| AU5702201A (en) | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| CA2357450A1 (en) | 2000-09-29 | 2002-03-29 | Warner-Lambert Company | Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis |
| WO2002048150A2 (en) * | 2000-11-02 | 2002-06-20 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof |
| JP2006517925A (ja) * | 2003-01-14 | 2006-08-03 | メルク エンド カムパニー インコーポレーテッド | Aβ42低下薬としてのジェミナル二置換NSAID誘導体 |
| JP4769718B2 (ja) * | 2003-08-07 | 2011-09-07 | メルク シャープ エンド ドーム リミテッド | アルツハイマー病及び関連症状の治療 |
-
2004
- 2004-05-07 GB GBGB0410238.0A patent/GB0410238D0/en not_active Ceased
-
2005
- 2005-05-06 DE DE602005015697T patent/DE602005015697D1/de not_active Expired - Lifetime
- 2005-05-06 AT AT05740478T patent/ATE437855T1/de not_active IP Right Cessation
- 2005-05-06 WO PCT/GB2005/001756 patent/WO2005108362A1/en not_active Ceased
- 2005-05-06 CN CNA2005800145866A patent/CN1950337A/zh active Pending
- 2005-05-06 CA CA002565214A patent/CA2565214A1/en not_active Abandoned
- 2005-05-06 US US11/587,779 patent/US7728022B2/en not_active Expired - Fee Related
- 2005-05-06 AU AU2005240830A patent/AU2005240830B2/en not_active Ceased
- 2005-05-06 JP JP2007512326A patent/JP2007536360A/ja active Pending
- 2005-05-06 EP EP05740478A patent/EP1748982B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005108362A1 (en) | 2005-11-17 |
| AU2005240830A1 (en) | 2005-11-17 |
| US7728022B2 (en) | 2010-06-01 |
| CN1950337A (zh) | 2007-04-18 |
| EP1748982B1 (de) | 2009-07-29 |
| GB0410238D0 (en) | 2004-06-09 |
| AU2005240830B2 (en) | 2011-03-24 |
| JP2007536360A (ja) | 2007-12-13 |
| EP1748982A1 (de) | 2007-02-07 |
| CA2565214A1 (en) | 2005-11-17 |
| DE602005015697D1 (de) | 2009-09-10 |
| US20070232678A1 (en) | 2007-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
| ATE455763T1 (de) | Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| ATE502633T1 (de) | Cyclosporins zur behandlung und vorbeugung von augenerkrankungen | |
| GB0318447D0 (en) | Therapeutic agents | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| DK1594833T3 (da) | 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| BRPI0417543A (pt) | quinolinas úteis no tratamento de doença cardiovascular | |
| ATE383853T1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| WO2009067493A3 (en) | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders | |
| ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
| ATE392471T1 (de) | Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| DE602005015697D1 (de) | Te zur behandlung von alzheimer-krankheit | |
| ATE496534T1 (de) | Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| ATE424195T1 (de) | Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen | |
| ATE524171T1 (de) | Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit | |
| DE602005014632D1 (de) | Pyrrol- bzw. imidazolamide zur behandlung von obesitas | |
| DE602004030661D1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |